After matching Comirnaty, Providence plans phase 3 booster study for COVID-19 vaccine candidate

Almost two years after phase 3 results on the leading COVID-19 vaccines started rolling in, Providence Therapeutics has posted midphase data on its mRNA candidate and outlined plans to move into a pivotal booster study.